Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Coverage

Latest content

Antti Siltanen

Analyst

Antti Siltanen portrait

Coverage

Herantis PharmaNexstimFaron PharmaceuticalsNightingale HealthBioretecAiforia TechnologiesBiohitOrionModulight

Latest content

ShowingAll content types

Bioretec received FDA approval for a new Activa product

Analyst Comment 2026-09-07 08:15 by Antti Siltanen
Bioretec

Aiforia H1'26: Still a long way to go before reaching profitability

Research 2026-08-31 13:26 by Antti Siltanen, Antti Luiro
Aiforia Technologies

Faron H1'26: New trials set to get underway

Research 2026-08-27 10:20 by Antti Siltanen
Faron Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account

Aiforia lands new partnership in breast cancer diagnostics

Analyst Comment 2026-08-26 09:59 by Antti Siltanen
Aiforia Technologies

Aiforia H1'26 preview: Profit warning increased concerns about commercial progress

Analyst Comment 2026-08-26 12:00 by Antti Siltanen
Aiforia Technologies

Faron H1'26 preview: BEXERA trial is being initiated

Analyst Comment 2026-08-25 09:37 by Antti Siltanen
Faron Pharmaceuticals

Modulight Q2'26: Pricing under pressure

Research 2026-08-24 10:20 by Antti Siltanen
Modulight

Herantis H1'26: Phase 2 preparation is progressing

Research 2026-08-21 09:08 by Antti Siltanen
Herantis Pharma

Biohit: GastroPanel Quick Test also works during proton pump inhibitor therapy

Analyst Comment 2026-08-19 08:27 by Antti Siltanen
Biohit

Nightingale's remote tests to be included in Supernormal's weight loss service

Analyst Comment 2026-08-19 09:12 by Antti Siltanen
Nightingale Health